Guardant Health director sells 9,294 shares

Guardant Health director Steve E. Krognes sold shares in an open-market transaction.

Rhea-AI Filing Summary

Guardant Health director Steve E. Krognes sold shares in an open-market transaction. He sold 9,294 shares of Guardant Health common stock on June 4, 2026 at a weighted average price of $132.5072 per share, in multiple trades priced between $132.50 and $132.71. After this sale, he directly owns 10,222 Guardant Health shares.

Insider Trade Summary

Net Seller: 9,294 shares

Net Sell 1 txn

Insider Krognes Steve E.

Role Director

Sold 9,294 shs ($1.23M)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,294	$132.5072	$1.23M

Holdings After Transaction: Common Stock — 10,222 shares (Direct)

Footnotes (1)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.50 to $132.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 9,294 shares Weighted average sale price: $132.5072 per share Post-transaction holdings: 10,222 shares +1 more

4 metrics

Shares sold 9,294 shares Open-market sale of common stock on June 4, 2026

Weighted average sale price $132.5072 per share Average price for 9,294 shares sold

Post-transaction holdings 10,222 shares Common stock directly owned after sale

Sale price range $132.50–$132.71 per share Range of prices for multiple sale transactions

Key Terms

open-market sale, weighted average sales price, Common Stock, Form 4

4 terms

open-market sale financial

"He sold 9,294 shares of Guardant Health common stock in an open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"Represents the weighted average sales price per share. These shares were sold"

Common Stock financial

"He sold 9,294 shares of Guardant Health common stock on June 4, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"Steve E. Krognes reported an open-market sale of Guardant Health common stock in this Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Guardant Health (GH) director Steve E. Krognes report in this Form 4?

Steve E. Krognes reported an open-market sale of Guardant Health common stock. He sold 9,294 shares on June 4, 2026, at a weighted average price of $132.5072 per share, and now directly holds 10,222 shares after the transaction.

How many Guardant Health (GH) shares did Steve E. Krognes sell and at what price?

He sold 9,294 Guardant Health common shares in the open market. The weighted average sale price was $132.5072 per share, with individual trades executed between $132.50 and $132.71 according to the Form 4 disclosure footnote.

How many Guardant Health (GH) shares does Steve E. Krognes own after this sale?

Following the reported transaction, Steve E. Krognes directly owns 10,222 shares of Guardant Health common stock. This figure is disclosed in the Form 4 as the total number of shares beneficially owned after completion of the June 4, 2026 sale.

Was the Guardant Health (GH) insider trade an open-market sale?

Yes. The Form 4 classifies the transaction as an open-market sale of common stock, coded “S.” The filing describes it as a sale in the open market or private transaction, with trades executed in a price range from $132.50 to $132.71 per share.

Did the Guardant Health (GH) Form 4 mention a price range for the shares sold?

Yes. The footnote states that the 9,294 shares were sold in multiple transactions at prices ranging from $132.50 to $132.71 per share, with a weighted average sales price of $132.5072 for the reported Guardant Health common stock sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 07:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S		9,294	D	$132.5072(1)	10,222	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.50 to $132.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)